- Detroit porch shooting trial: Suspect says he didn’t know gun was loaded
- U.S. Navy admiral ‘receptive’ to giving Chinese counterpart a tour of carrier
- Islamic State orders female genital mutilation for Mosul girls, U.N. says
- Israeli fire hits U.N. facility in Gaza, killing 15
- Obama encourages ICE to stand down, say former border agents
- Pro-Palestinian protesters attack Israeli soccer team in Austria match
- Virginia police: 2 dead after storm at campground
- Ukrainian prime minister announces resignation
- House members question $17 billion VA request
- N.Y. Gov. Cuomo launches statewide task force to collect LGBT data
LETTER TO THE EDITOR: Alzheimer’s needs better diagnostics
Question of the Day
As I read through Wayne Winegarden’s “Treating Alzheimer’s with regulations” (Commentary, May 7), I was overcome by many of the statistics surrounding the neurodegenerative disorder. It is clear that Alzheimer’s disease is becoming as expansive as it is expensive, but I found myself asking if Medicare is neglectful of rising costs associated with the disease, or if it is wary of the nascent applications of nuclear medicine.
The emerging use of Positron Emission Tomography (PET) scans to detect neurological degeneration has a great deal of potential. More exciting is the ability to use molecular tracers to detect beta amyloid plaques, depositions of cellular proteins that are strongly correlated with Alzheimer’s progression.
However, there are several questions surrounding PET scans that keep amyloid beta plaques from being routinely indicated. Beta amyloid deposition and neurodegeneration have been shown to precede symptoms of Alzheimer’s by 20 to 30 years. So when is it appropriate to start screening? At the start of symptoms? Thirty years before the average age of onset? How reliable is the test for distinguishing beta amyloid Alzheimer’s from other forms of dementia, or even from the normal aging process?
Currently, the standard of care hasn’t been established. It is for this reason that most private insurance companies, in addition to Medicare, do not consider PET scans to be worth their price tag of several thousand dollars, nor do they consider them to be clinically indicated in Alzheimer’s (Aetna, CIGNA and others consider PET scans for Alzheimer’s “experimental, investigational or unproven”).
Perhaps government intervention isn’t an answer in many ways, but it has been on the cutting edge of diagnostic and imaging research in Alzheimer’s. The National Institute of Neurological Disorders and Stroke, as well as the National Institute of Biomedical Imaging and Bioengineering, have started several projects in an effort to learn more about Alzheimer’s. The Obama administration has even increased clinical trial funding for diagnostics and treatment as part of its “National Plan to Address Alzheimer’s Disease” by 2025.
Mr. Winegarden makes an excellent point that these tests need to be explored further. They need research and standardization so such an expensive test isn’t used unless absolutely necessary. I think he will agree that means a shifting of support to the right areas of research and health care.
© Copyright 2014 The Washington Times, LLC. Click here for reprint permission.
TWT Video Picks
The subsidies are a hit with patients who don't exist
Get Breaking Alerts
- Hamas rejects Kerry's call for cease-fire; Fears grow others could join fight against Israel
- Obama's empty tough-talk: Gun prosecutions plummet on his watch
- Algerian plane diverted due to storms, second aircraft: 116 missing
- Whistleblowers flood VA with lawsuits despite apology
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- Obama says public not familiar enough with issues
- Obama dispatches researchers to border to check on National Guard
- NAPOLITANO: What if our democracy is a fraud?
- Astronaut shares 'saddest photo' from space: Bombs bursting over Israel, Gaza
- Conservative groups decry Democrats' 'war on women' tactic